Thursday, 19 Sep 2019

You are here

Dr. Arthur Kavanaugh: Biosimilars and Drug Switching (Abstract 19L)

Dr. Arthur Kavanaugh discusses abstract 19L: Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway, as presented at the 2016 ACR/ARHP Annual Meeting (http://acrabstracts.org/abstract/biosimilar-infliximab-ct-p13-is-not-inferior-to-originator-infliximab-results-from-a-52-week-randomized-switch-trial-in-norway/).

Add new comment

Want to talk about this video? Comment here to lead the discussion.
MORE VIDEOS

Dr. Rachel T. Huston: Drug Exposure in...

01 Dec 2016

RheumNow Week in Review – The Heart...

02 Nov 2018

Dr. Bernie Rubin: Fellows Program at...

09 Feb 2018

Dr. Olga Petryna: Cardiovascular risk...

12 Jun 2017

Dr Alex So Reflects on Days 1-3 Gout...

21 Jun 2019

Dr. Paul Emery: The Optimal Use of...

15 Feb 2019

Dr. Arthur Kavanaugh: RA and Treatment...

09 Feb 2018

Psoriatic Arthritis and the Elevated...

15 Jan 2019

RheumNow Podcast - Scurvy and Mechanics...

01 Feb 2019

Dr. Kathryn Dao: Evidence of Prior...

06 Nov 2017

The RheumNow Week in Review – Vitamin D...

20 Apr 2018

Dr. Jeffrey Chwa: A "Large"...

09 Feb 2018